Tislelizumab
2025 (196)
Phase 2 small_molecule active
Quick answer
Tislelizumab for Head and Neck Squamous Cell Carcinoma is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Head and Neck Squamous Cell Carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active